Lataa...
Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
Objective: To evaluate the cost-effectiveness of dabrafenib plus trametinib combination therapy versus vemurafenib as first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma from a healthcare system perspective in China. Methods: This study employed a pa...
Tallennettuna:
| Julkaisussa: | Int J Environ Res Public Health |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8226451/ https://ncbi.nlm.nih.gov/pubmed/34201096 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijerph18126194 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|